The U.S. FDA says it has been alerted to the first manufacturing shortage of a drug due to the COVID-19 outbreak.
The agency did not name the manufacturer, but says the shortage is related to a an issue with the active pharmaceutical ingredient site impacted by the outbreak in China.
Recent estimates say that China controls as much as 80 percent of the global API supply.
The FDA says it has been in touch with more than 180 drug manufacturers since Jan. 24, asking them to evaluate their entire supply chain and other components manufactured in China.
Read the FDA supply chain update
See the FDA shortage list